Chaperone-Based Therapeutic Target Innovation: Heat Shock Protein 70 (HSP70) for Type 2 Diabetes Mellitus

W. Riski Widya Mulyani,1 Made Indira Dianti Sanjiwani,1 Sandra,1 I Putu Yuda Prabawa,2 Anak Agung Wiradewi Lestari,2 Desak Made Wihandani,3 Ketut Suastika,4 Made Ratna Saraswati,4 Agha Bhargah,1,5 Ida Bagus Amertha Putra Manuaba6,7 1Faculty of Medicine, Universitas Udayana, Bali, Indonesia; 2Departm...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mulyani WRW, Sanjiwani MID, Sandra, Prabawa IPY, Lestari AAW, Wihandani DM, Suastika K, Saraswati MR, Bhargah A, Manuaba IBAP
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	type 2 diabetes mellitus hsp70 insulin resistance. Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/8ce3edd7ec944ce28679c9254fdc6a7a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8ce3edd7ec944ce28679c9254fdc6a7a
record_format	dspace
spelling	oai:doaj.org-article:8ce3edd7ec944ce28679c9254fdc6a7a2021-12-02T09:09:07ZChaperone-Based Therapeutic Target Innovation: Heat Shock Protein 70 (HSP70) for Type 2 Diabetes Mellitus1178-7007https://doaj.org/article/8ce3edd7ec944ce28679c9254fdc6a7a2020-02-01T00:00:00Zhttps://www.dovepress.com/chaperone-based-therapeutic-target-innovation-heat-shock-protein-70-hs-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007W. Riski Widya Mulyani,1 Made Indira Dianti Sanjiwani,1 Sandra,1 I Putu Yuda Prabawa,2 Anak Agung Wiradewi Lestari,2 Desak Made Wihandani,3 Ketut Suastika,4 Made Ratna Saraswati,4 Agha Bhargah,1,5 Ida Bagus Amertha Putra Manuaba6,7 1Faculty of Medicine, Universitas Udayana, Bali, Indonesia; 2Department of Clinical Pathology, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia; 3Department of Biochemistry, Faculty of Medicine, Universitas Udayana, Bali, Indonesia; 4Department of Internal Medicine, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia; 5Cardiology Department, Faculty of Medicine, Universitas Udayana-Sanglah General Hospital, Bali, Indonesia; 6International Ph.D Program in Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; 7Medical and Health Education Unit, Faculty of Medicine, Universitas Udayana, Bali, IndonesiaCorrespondence: Anak Agung Wiradewi LestariDepartment of Clinical Pathology, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, IndonesiaEmail wiradewilestari@gmail.comAbstract: Type 2 diabetes mellitus (T2DM) is still a global health problem. Current T2DM treatments are limited to curing the symptoms and have not been able to restore insulin sensitivity in insulin-sensitive tissues that have become resistant. In the past decade, some studies have shown the significant role of a chaperone family, heat shock protein 70 (HSP70), in insulin resistance pathogenesis that leads to T2DM. HSP70 is a cytoprotective molecular chaperone that functions in protein folding and degradation. In general, studies have shown that decreased concentration of HSP70 is able to induce inflammation process through JNK activation, inhibit fatty acid oxidation by mitochondria through mitophagy decrease and mitochondrial biogenesis, as well as activate SREBP-1c, one of the lipogenic gene transcription factors in ER stress. The overall molecular pathways are potentially leading to insulin resistance and T2DM. Increased expression of HSP70 in brain tissues is able to improve insulin sensitivity and glycemic control specifically. HSP70 modulation-targeting strategies (including long-term physical exercise, hot tub therapy (HTT), and administration of alfalfa-derived HSP70 (aHSP70)) in subjects with insulin resistance are proven to have therapeutic and preventive potency that are promising in T2DM management.Keywords: type 2 diabetes mellitus, HSP70, insulin resistanceMulyani WRWSanjiwani MIDSandraPrabawa IPYLestari AAWWihandani DMSuastika KSaraswati MRBhargah AManuaba IBAPDove Medical Pressarticletype 2 diabetes mellitushsp70insulin resistance.Specialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 13, Pp 559-568 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	type 2 diabetes mellitus hsp70 insulin resistance. Specialties of internal medicine RC581-951
spellingShingle	type 2 diabetes mellitus hsp70 insulin resistance. Specialties of internal medicine RC581-951 Mulyani WRW Sanjiwani MID Sandra Prabawa IPY Lestari AAW Wihandani DM Suastika K Saraswati MR Bhargah A Manuaba IBAP Chaperone-Based Therapeutic Target Innovation: Heat Shock Protein 70 (HSP70) for Type 2 Diabetes Mellitus
description	W. Riski Widya Mulyani,1 Made Indira Dianti Sanjiwani,1 Sandra,1 I Putu Yuda Prabawa,2 Anak Agung Wiradewi Lestari,2 Desak Made Wihandani,3 Ketut Suastika,4 Made Ratna Saraswati,4 Agha Bhargah,1,5 Ida Bagus Amertha Putra Manuaba6,7 1Faculty of Medicine, Universitas Udayana, Bali, Indonesia; 2Department of Clinical Pathology, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia; 3Department of Biochemistry, Faculty of Medicine, Universitas Udayana, Bali, Indonesia; 4Department of Internal Medicine, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia; 5Cardiology Department, Faculty of Medicine, Universitas Udayana-Sanglah General Hospital, Bali, Indonesia; 6International Ph.D Program in Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; 7Medical and Health Education Unit, Faculty of Medicine, Universitas Udayana, Bali, IndonesiaCorrespondence: Anak Agung Wiradewi LestariDepartment of Clinical Pathology, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, IndonesiaEmail wiradewilestari@gmail.comAbstract: Type 2 diabetes mellitus (T2DM) is still a global health problem. Current T2DM treatments are limited to curing the symptoms and have not been able to restore insulin sensitivity in insulin-sensitive tissues that have become resistant. In the past decade, some studies have shown the significant role of a chaperone family, heat shock protein 70 (HSP70), in insulin resistance pathogenesis that leads to T2DM. HSP70 is a cytoprotective molecular chaperone that functions in protein folding and degradation. In general, studies have shown that decreased concentration of HSP70 is able to induce inflammation process through JNK activation, inhibit fatty acid oxidation by mitochondria through mitophagy decrease and mitochondrial biogenesis, as well as activate SREBP-1c, one of the lipogenic gene transcription factors in ER stress. The overall molecular pathways are potentially leading to insulin resistance and T2DM. Increased expression of HSP70 in brain tissues is able to improve insulin sensitivity and glycemic control specifically. HSP70 modulation-targeting strategies (including long-term physical exercise, hot tub therapy (HTT), and administration of alfalfa-derived HSP70 (aHSP70)) in subjects with insulin resistance are proven to have therapeutic and preventive potency that are promising in T2DM management.Keywords: type 2 diabetes mellitus, HSP70, insulin resistance
format	article
author	Mulyani WRW Sanjiwani MID Sandra Prabawa IPY Lestari AAW Wihandani DM Suastika K Saraswati MR Bhargah A Manuaba IBAP
author_facet	Mulyani WRW Sanjiwani MID Sandra Prabawa IPY Lestari AAW Wihandani DM Suastika K Saraswati MR Bhargah A Manuaba IBAP
author_sort	Mulyani WRW
title	Chaperone-Based Therapeutic Target Innovation: Heat Shock Protein 70 (HSP70) for Type 2 Diabetes Mellitus
title_short	Chaperone-Based Therapeutic Target Innovation: Heat Shock Protein 70 (HSP70) for Type 2 Diabetes Mellitus
title_full	Chaperone-Based Therapeutic Target Innovation: Heat Shock Protein 70 (HSP70) for Type 2 Diabetes Mellitus
title_fullStr	Chaperone-Based Therapeutic Target Innovation: Heat Shock Protein 70 (HSP70) for Type 2 Diabetes Mellitus
title_full_unstemmed	Chaperone-Based Therapeutic Target Innovation: Heat Shock Protein 70 (HSP70) for Type 2 Diabetes Mellitus
title_sort	chaperone-based therapeutic target innovation: heat shock protein 70 (hsp70) for type 2 diabetes mellitus
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/8ce3edd7ec944ce28679c9254fdc6a7a
work_keys_str_mv	AT mulyaniwrw chaperonebasedtherapeutictargetinnovationheatshockprotein70hsp70fortype2diabetesmellitus AT sanjiwanimid chaperonebasedtherapeutictargetinnovationheatshockprotein70hsp70fortype2diabetesmellitus AT sandra chaperonebasedtherapeutictargetinnovationheatshockprotein70hsp70fortype2diabetesmellitus AT prabawaipy chaperonebasedtherapeutictargetinnovationheatshockprotein70hsp70fortype2diabetesmellitus AT lestariaaw chaperonebasedtherapeutictargetinnovationheatshockprotein70hsp70fortype2diabetesmellitus AT wihandanidm chaperonebasedtherapeutictargetinnovationheatshockprotein70hsp70fortype2diabetesmellitus AT suastikak chaperonebasedtherapeutictargetinnovationheatshockprotein70hsp70fortype2diabetesmellitus AT saraswatimr chaperonebasedtherapeutictargetinnovationheatshockprotein70hsp70fortype2diabetesmellitus AT bhargaha chaperonebasedtherapeutictargetinnovationheatshockprotein70hsp70fortype2diabetesmellitus AT manuabaibap chaperonebasedtherapeutictargetinnovationheatshockprotein70hsp70fortype2diabetesmellitus
_version_	1718398256743972864

Chaperone-Based Therapeutic Target Innovation: Heat Shock Protein 70 (HSP70) for Type 2 Diabetes Mellitus

Ejemplares similares